Peptide Therapy · PT-141 & Melanotans

PT-141, Melanotan I, and Melanotan II: Same Family, Very Different Drugs

Compare bremelanotide (PT-141), Melanotan I/afamelanotide, and Melanotan II by receptors, approved uses, evidence, risks, and legal status.

Medical reviewer: Dr. Kish Carlton, MD · Mind Body Spirit Medicine · Last reviewed · 10 min read

PT-141 and Melanotan episode thumbnail: Dr. Kish Carlton, MD in navy scrubs beside the title “Same family. Different effects.” with markers for PT-141, Melanotan I, and Melanotan II.

Watch the episode

One signaling family does not mean one clinical product

Bremelanotide, historically known by the research code PT-141, Melanotan I, and Melanotan II are chemically related to alpha-melanocyte-stimulating hormone. That shared lineage explains why their names often appear together online. It does not make them interchangeable.

One is the active ingredient in an approved prescription autoinjector for a narrowly defined sexual-desire disorder. One is closely related to the historical research name for afamelanotide, the active ingredient in an approved implant for erythropoietic protoporphyria. The third remains an unapproved research peptide with sparse human data and major product-identity concerns in the gray market.

The easiest way to remember the difference is to imagine the melanocortin system as a biological control panel. Related molecules can reach the same panel while pressing different combinations of receptor “buttons.” Those differences shape pigmentation, central nervous-system effects, side effects, clinical evidence, and regulatory status.

The melanocortin control panel

Five melanocortin receptor subtypes are distributed across the skin, brain, endocrine system, immune tissues, and other organs.

Melanocortin 1 receptor is strongly associated with melanocyte signaling and the production of eumelanin, the darker form of melanin. Central melanocortin 3 and 4 receptor pathways participate in energy balance, appetite, motivation, and sexual behavior. Melanocortin 5 receptor is more broadly distributed in peripheral tissues and remains an active area of research.

This biology is interconnected rather than perfectly compartmentalized. Saying that one receptor is “the pigment button” or that another is central to sexual signaling is a useful memory device, not proof that every observed effect belongs to a single receptor.

Melanotan I and afamelanotide

Melanotan I is a historical research name associated with the linear alpha-melanocyte-stimulating-hormone analogue now called afamelanotide. Afamelanotide is principally a melanocortin 1 receptor agonist.

The naming distinction matters because afamelanotide is a defined active pharmaceutical ingredient, while SCENESSE is a specific regulated product: a 16-milligram subcutaneous implant administered by a trained healthcare professional. An online vial labeled “Melanotan I” is not automatically afamelanotide and is not automatically equivalent to SCENESSE.

The Food and Drug Administration approved SCENESSE in 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. This rare condition can produce severe pain after light exposure. In randomized trials, afamelanotide increased pain-free light exposure and improved quality of life in affected patients.

That approval is not an approval for cosmetic tanning, and afamelanotide should not be described as a sunscreen substitute. Because its pharmacology increases pigmentation, current labeling warns that existing freckles and moles may darken and recommends full-body skin examinations twice yearly to monitor existing and new pigmented lesions. Serious hypersensitivity reactions, including anaphylaxis, have also been reported.

Melanotan II: potent, broad, and inadequately characterized

Melanotan II is a shorter cyclic analogue that is relatively nonselective across melanocortin receptor subtypes. Its broad receptor activity helps explain why research has produced effects extending beyond pigmentation.

The early human evidence is remarkably small. A 1996 phase 1 pilot included only three healthy men. Investigators reported increased pigmentation, nausea at multiple exposure levels, and fatigue or somnolence at higher exposure. Sexual effects were also noticed during the pigmentation development program.

Those unexpected observations influenced a separate drug-development pathway. Research on a shortened metabolite led to the compound originally coded PT-141 and now known as bremelanotide.

Melanotan II itself did not become an approved tanning drug, weight-loss drug, erectile-dysfunction treatment, or sexual-enhancement drug. Claims about appetite suppression and weight loss have mechanistic and animal support through central melanocortin biology, but they are not established human clinical outcomes.

Case reports describe ischemic priapism requiring emergency treatment and rapid or atypical changes in pigmented lesions following Melanotan II use. These reports do not establish that Melanotan II causes melanoma. They do reinforce that changing moles should be assessed clinically rather than dismissed as an expected cosmetic effect.

Bremelanotide: related chemistry, distinct clinical identity

Bremelanotide preserves a cyclic core related to Melanotan II but is a distinct defined molecule. Food and Drug Administration review materials describe activity at melanocortin receptors 1, 3, 4, and 5. Central melanocortin 4 receptor signaling is considered particularly relevant to sexual function, although the complete human mechanism for the approved indication remains unknown.

The approved product VYLEESI is a subcutaneous autoinjector. It is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder when low desire causes marked distress or interpersonal difficulty and is not due to another medical or psychiatric condition, relationship problem, medication, or drug substance.

It is not approved for postmenopausal women, men, erectile dysfunction, or enhancement of sexual performance.

In pivotal trials, bremelanotide improved measures of sexual desire and reduced associated distress compared with placebo. The trials did not show a statistically significant difference in the number of satisfying sexual events, a secondary endpoint. The evidence therefore supports a nuanced claim about desire and distress—not a universal performance-enhancement claim.

Safety profiles are different, too

Approved bremelanotide labeling describes transient increases in blood pressure with reductions in heart rate. The product is contraindicated in uncontrolled hypertension and known cardiovascular disease. Nausea is common and can be severe. Other concerns include flushing, headache, injection-site reactions, and focal hyperpigmentation that may not fully resolve. Slowed gastric motility may alter absorption of some oral medicines.

Afamelanotide’s regulated clinical workflow includes implant-site risks, nausea, pigmentation changes, monitoring of existing and new lesions, and attention to serious hypersensitivity.

With gray-market Melanotan II, uncertainty about the product is itself a material risk. Identity, concentration, purity, sterility, storage, and labeling may be unknown. Food and Drug Administration records describe enforcement against unapproved Melanotan II products, and import records illustrate broader concerns about peptide identity and undeclared ingredients.

Approved, compounded, research, and gray-market are not synonyms

An approved drug has a reviewed application, defined formulation, controlled manufacturing, official labeling, and one or more specific approved indications.

A compounded drug is not Food and Drug Administration approved. Compounding may be lawful under defined circumstances, but the preparation does not automatically share the approved product’s evidence, manufacturing controls, pharmacokinetics, or labeling. Eligibility depends on the exact substance and applicable federal and state requirements.

A research chemical is intended for laboratory work. A “research use only” disclaimer does not establish that a product is safe, pure, sterile, or lawful for human administration.

An online “tanning peptide” is a marketing term, not a regulatory category. It may refer to Melanotan I, Melanotan II, a mislabeled peptide, a mixture, or an entirely different substance.

Evidence scoreboard

Supported and approved: Afamelanotide increases pain-free light exposure in adults with erythropoietic protoporphyria. Bremelanotide improves sexual desire and reduces associated distress in the narrowly defined approved premenopausal population.

Preliminary human evidence: Melanotan II can increase pigmentation and can produce sexual and adverse effects, but the available human research is sparse and does not establish an approved clinical use.

Plausible but unproven: Melanotan II may affect appetite and energy balance through central melanocortin pathways. A plausible mechanism is not a proven weight-loss outcome.

Overstated or unsupported: Melanotan II is a safe sexual enhancer; any of these compounds prevents skin cancer; induced pigmentation makes ultraviolet exposure safe; or an online peptide is interchangeable with an approved drug.

Bottom line

These compounds are fascinating precisely because they are not three versions of the same peptide. Small structural changes can redirect a shared signaling family toward different receptor patterns, clinical programs, therapeutic outcomes, side effects, and regulatory controls.

Chemical resemblance is the beginning of the comparison—not the conclusion.

Work with Dr. Kish Carlton

If you’re interested in working with Dr. Kish Carlton and Mind Body Spirit Medicine, learn more at www.MindBodySpirit-DPC.com. This is a low-pressure next step for readers who want to explore whether the practice is a good fit for their goals.

References

Medical disclaimer

This article is for education only and is not individualized medical advice, diagnosis, treatment, dosing, reconstitution, or purchasing guidance. Seek prompt medical evaluation for a new or changing pigmented lesion, prolonged erection, severe nausea, chest symptoms, or concerning blood-pressure symptoms.